Overall verdict
Buy
6.8/10
1-year performance
+36.95%
Score breakdown
Up 36.9% over 1 year, 89% of the 52-week range.
Strongest: Profitability 7.9/10. Weakest: Financial strength 3.5/10.
22 analysts, target +0.1% vs the price.
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members ; health products ; a broad array of fee-based administrative managed care services ;
and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business ; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers.
In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains ; behavioral health and comprehensive care management services ; palliative care services and management ; virtual care ; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs ;
and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.
Sector
Health Care
Industry
Health Care Providers and Services
Primary listing
Nyse
United States
CEO
Gail Boudreaux
Founded
2001
Employees
97 100
Revenue / employee
2.1M USD
Next earnings
January 27, 2027 (estimated)
Institutional holders
- GEODE CAPITAL MANAGEMENT, LLC2.41%
- Bank of New York Mellon Corp1.59%
- FMR LLC1.10%
- Rest of the register94.89%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
450.69 USD
52-week low
274.84 USD
1-year performance
36.95%
Rising
Year-to-date performance
22.97%
Rising
Drawdown
-4.30%
Near its high
Position in the 52-week range
89% of range
Against the world ETF
Over 26 years, from December 2000 to October 2026, the share did better than the world ETF once risk is accounted for.
$10,000 placed at the end of December 2000 are worth today
| Elevance Health | $185,127 |
| World ETF | $65,117 |
| S&P 500 | $91,204 |
| Risk-free placement | $15,894 |
The risk
- Shaking:the share moves 1.9 times as much as the world ETF.
- Worst fall:-61Â % between December 2007 and February 2009. $10,000 placed at the top fell to $3,866. The world ETF, at worst: -53Â %. Back to its high in 53 months.
Elevance Health earned 3 times as much as the world ETF since 2000
Value of $10,000 placed at the end of December 2000, dividends reinvested, in dollars
- Elevance Health: $185,127
- World ETF: $65,117
- S&P 500: $91,204
- Risk-free placement: $15,894
Based on past performance. This is not a recommendation.
Range: 406.00 USD - 497.77 USD (3 methods agree)
The price implies growth of 0.60% per year; the company grows at 6.99%.
Gross margin 89.0%, net margin 2.5%, ROIC 6.8%, ROE 11.6%.
Net margin
2.55%
Exceptional
Sector 0.76%|S&P 13.40%
Gross margin
89.04%
Exceptional
Return on equity (ROE)
11.60%
High
Sector 8.65%|S&P 17.06%
Return on invested capital (ROIC)
6.84%
Exceptional
Free cash flow margin (FCF)
3.23%
Fair
Profit-to-cash conversion (FCF conversion)
1.27x
Fair
Margin stability
0.6 pts
Very steady
Revenue to net income
Growth
7.7/10Revenue up 1.4% over 1 year, 10.3% a year over 5, EPS 7.0% a year over 5.
Revenue (trailing 12 months)
202Md USD
Revenue growth (1y)
1.42%
Moderate
Revenue growth (3y)
27.16%
Solid
EPS growth (1y)
18.02%
Strong
EPS CAGR (5y)
6.99%
Low
EPS revisions (3 months)
7.29%
Sharply revised up
Valuation
6.5/10P/E 18.4x, forward P/E 19.2x, EV/EBITDA 16.4x, PEG 2.63. The multiple sits in the 43th percentile of its own 5-year history.
P/E (TTM)
18.4x
Cheap
Sector 35.3x|S&P 23.6x
Forward P/E
19.2x
Fair
EV / EBITDA
16.4x
Fair
Sector 18.5x|S&P 15.5x
PEG
2.63
Very expensive
Sector -0.20|S&P 0.91
Fair value (reverse DCF)
481.17 USD
Undervalued
P/E vs its own 5-year history
among the 43% lowest valuations
In line with its history
Market cap
93.2Md USD
Financial strength
3.5/10Cash covers 33.6% of the debt, net debt/EBITDA 3.0x.
Net debt / EBITDA
3.0x
Stretched
Gearing (net debt / equity)
45.56%
Solid
Cash
10.3Md USD
Cash / market cap
11.10%
Solid
Cash / total debt
33.64%
Solid
Interest coverage
3.8x
Tight
Net debt
20.4Md USD
Equity
44.8Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 429.65 USD
- MM20427.55
- MM50414.09
- MM200374.12
- RSI 1455.0
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+1.77%
200-day average slope, 3 months
+6.04%
50-day average slope, 1 month
+3.39%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.88 % per day
Volatility change
-1.00%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 22.43 (7) | 29.14 (21) | 198 847 (12) | 10 632 (7) | 4 845 (7) |
| 2027 | 28.17 (6) | 30.29 (21) | 203 748 (12) | 10 797 (7) | 6 059 (7) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 4, 2026.
Same sub-industry: 10 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PGNY | 7.2 | 7.5 | 2.7Md USD | 33.5x | 6.8 % | 8.9 % | 17.8 % | -3.1x | 6.7 % | 53.4 % | ||
| 2 | HQY | 7.0 | 6.8 | 8.5Md USD | 37.2x | 17.4 % | 7.6 % | 7.7 % | 1.4x | 5.7 % | 3.4 % | ||
| 3 | ELV | 6.8 | 6.7 | 93.2Md USD | 18.4x | 2.5 % | 1.4 % | 6.8 % | 3.0x | 7.0 % | 36.9 % | ||
| 4 | UNH | 6.8 | 6.7 | 361Md USD | 23.0x | 3.5 % | -0.4 % | 9.5 % | 1.8x | 6.3 % | 24.6 % | ||
| 5 | SAUD3 | 6.4 | 5.9 | 8.4Md USD | 16.8x | 10.6 % | 1213.1 % | 10.4 % | -0.3x | 1.5 % | 36.5 % | ||
| 6 | CNC | 5.8 | 5.8 | 34.9Md USD | 24.2x | 0.7 % | 1.9 % | 3.8 % | -1.4x | 11.3 % | 102.9 % | ||
| 7 | HUM | 4.9 | 3.5 | 53.6Md USD | 43.4x | 0.8 % | 26.1 % | 4.1 % | -2.2x | 5.9 % | 86.0 % | ||
| 8 | MOH | 4.7 | 2.8 | 10.9Md USD | Not meaningful (loss) | -0.1 % | -3.4 % | -0.6 % | -22.1x | 2.2 % | 47.1 % | ||
| 9 | CLOV | 4.3 | 1.9 | 2.6Md USD | 263.0x | 0.5 % | 52.9 % | — | — | — | 91.2 % |
